A PYMNTS Company

US: Judge demands settlement documents from Boehringer

By  |  September 29, 2016

A federal judge has ordered Boehringer Ingelheim Pharmaceuticals Inc to turn over several documents related to settlements it reached with generic rival Barr Laboratories to the Federal Trade Commission, finding they are not protected as work product prepared in anticipation of litigation.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    Subscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The FTC is looking into whether the 2008 settlements, which resolved patent claims asserted by Boehringer against Barr over its anti-clotting drug Aggrenox and Parkinson’s drug Mirapex, involved illegal payments to Barr to delay generic versions.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.